Abstracts tisements increased awareness of new treatment (perceived benefit) and improved discussion with health professionals (perceived benefit) were both positively associated with switching request (p = 0.001 and p < 0.0001, respectively). Believing that DTC advertisements led to decreased confidence in doctor's judgment (perceived barrier) was negatively associated with switching request (p = 0.02). Patients on regular medication (OR, 2.03; 95% CI, 1.48-2.78), black patients (OR, 2.76; 95% CI, 1.48-5.13), patients with higher attentiveness to DTC advertising (p < 0.0001), and patients with allergies (OR, 1.35; 95% CI, 1.01-1.79), asthma (OR, 1.71; 95% CI, 1.09-4.33), or anxiety (OR, 1.60; 95% CI, 1.23-2.57), were more likely to make switching requests. CONCLUSIONS: Patients' switching requests were associated with health beliefs, race, health status, and attentiveness to DTC advertising. OBJECTIVES: To investigate the prevalence of potentially inappropriate medication prescribing (PIP) among elderly residents in Regione Emilia Romagna (RER), Italy and to examine factors associated with having PIP. METHODS: We conducted a retrospective cohort study using the 2001 outpatient prescription claims RER database. We linked individuals in this database with information (age, gender, and other variables) available from a demographic file of approximately 1 million elderly RER residents. The cohort comprised 849,425 subjects 65 years or older, who had at least one drug prescription during the study period. PIP was defined as having a prescription claim for a medication included in the 2003 Beers updated list of drugs to be avoided in the elderly. Of the 48 medications in the list, 19 were reimbursed in 2001 by the Italian National Formulary and included in the analysis. RESULTS: A total of 152,641 elderly in the cohort (18.0%) had 1 or more occurrences of PIP. Of these, 11.5% received prescriptions for 2 medications of concern and 1.7% for 3 or more. Doxazosin (23.0% of the subjects) was the most frequently occurring PIP, followed by ketorolac (20.5%), ticlopidine (18.3%), and amiodarone (12.6%). More than half of the PIP was for drugs with the potential for severe adverse outcomes. Factors associated with greater likelihood of PIP were male, older age, overall number of drugs prescribed, greater number of chronic conditions, and lower income level. CON-CLUSIONS: This study provides strong evidence that PIP for elderly ambulatory patients is a substantial problem in Italy. Because we were able to analyze only a fraction of the Beers' drugs list, our results underestimate the extent of PIP. The awareness of the prevalence of PIP and associated determinants may be useful in designing and implementing effective programs targeting outpatient practitioners to influence their prescribing behavior to reduce PIP.
Ben-Hamadi R 1 , Duh MS 1 , Aggarwal J 1 , Henckler A 1 , McKenzie S 2 , Fastenau J 3 , Piech CT 3 1 Analysis Group Inc, Boston, MA, USA; 2 Ortho Biotech Clinical Affairs LLC, Dallas, TX, USA; 3 Ortho Biotech Clinical Affairs LLC, Bridgewater, NJ, USA OBJECTIVES: To analyze the comparative cost effectiveness of epoetin alfa (EPO) and darbepoetin alfa (DARB) based on the FDA-approved doses for EPO (40,000 Units/week) and DARB (2.25 mcg/kg/week) for the treatment of chemotherapy-induced anemia (CIA). METHODS: Clinical results were drawn from two randomized, double blind, placebo-controlled phase III registration trials (EPO, N = 344 patients, JCO Sep 27, 2004 [Epub ahead of print] ; DARB N = 320 patients, JNCI 2002 JNCI 94:1211 abstract 981 Eur J Cancer 2001 37, Suppl 6: 264) . Effectiveness was based on the red blood cell transfusion rate between Week 5 and the end of Week 12 and was standardized as the difference in transfusion rates between the active drug and the respective placebo, divided by the transfusion rate for the placebo. Estimated costs were presented in 2004 USD and included drug, physician services, transfusions, laboratory, and patient opportunity costs. Cost-effectiveness was calculated as average cost divided by transfusion effectiveness. Threshold analysis was conducted by finding the break even point at which EPO and DARB have the same total cost and cost-effectiveness ratio, respectively. RESULTS: Estimated total cost over 12 weeks was $7,618 for EPO and $10,857 for DARB, with drug cost representing 85% and 89% for EPO and DARB, respectively. Relative to placebo, the standardized transfusion effectiveness was 65% for EPO and 48% for DARB, resulting in an average cost effectiveness ratio of $117 for EPO and $226 for DARB. A 33% (or 54%) reduction in DARB dose or price would be needed to equalize the total cost (or cost-effectiveness ratio) with that of EPO. CONCLUSIONS: Drug cost was determined to be the key driver of total cost. In addition, this analysis found EPO to be more effective in reducing blood transfusion requirements and less costly, and hence the dominant alternative compared to DARB for the treatment of CIA.
CN2

VALUE-FOR-MONEY OF PEMETREXED PLUS CISPLATIN VERSUS CISPLATIN ALONE IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Davey P 1 , Cordony A 1 , Rajan N 2 , Arora B 2 , Pavlakis N 3 1 Medical Technology Assessment Group Pty Ltd, Sydney, NSW, Australia; 2 Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia; 3 Royal North Shore Hospital, Sydney, NSW, Australia OBJECTIVES: To determine the value-for-money offered by pemetrexed (Alimta) plus cisplatin therapy for patients with malignant pleural mesothelioma (MPM), relative to cisplatin monotherapy, in Australia. MPM is an uncommon, locally invasive and rapidly fatal malignancy. There is currently no other drug reimbursed by the Australian National Formulary specifically for the treatment of mesothelioma. METHODS: A comprehensive literature search revealed one randomised headto-head trial of pemetrexed plus cisplatin therapy versus cisplatin monotherapy (N = 448), by Vogelzang et al. (2003) . Median survival for the intention-to-treat (ITT) population was 12.1 months for the pemetrexed plus cisplatin arm versus 9.3 months for the cisplatin arm (hazard ratio = 0.77, p = 0.020). Although there was greater toxicity with the combination regimen, quality of life was not negatively impacted. Mean survival time for each treatment arm was estimated from Kaplan-Meier survival curves. Resource use was applied as per the trial and costed accordingly. Study drug utilisation, concomitant medications, supplementary medication (dexamethasone, folic acid, and vitamin B 12 ), poststudy chemotherapy, and care for serious and treatment-emergent adverse events were costed. RESULTS: Patients received a mean of 4.7 treatment cycles in the pemetrexed plus cisplatin arm, and 4.0 cycles in the cisplatin monotherapy arm. The combination therapy required more supportive care for toxicities.
The additional mean cost of pemetrexed plus cisplatin therapy, over cisplatin monotherapy, was A$14,032.78 per patient. The mean and median survival gain with pemetrexed plus cisplatin therapy was found to be 0.191 and 0.233 years, respectively, relative to cisplatin monotherapy, over the 27-month period of observation. The cost per life-year saved was A$73,470.04 for mean and A$60,226.52 for median incremental survival. CON-CLUSION: This survival benefit is a highly patient-relevant outcome. This economic evaluation found that pemetrexed plus cisplatin therapy offers an acceptable cost-effectiveness ratio for a small population of MPM patients in Australia.
CN3 ONCOLOGISTS' COST-EFFECTIVENESS THRESHOLDS FOR NEW CANCER THERAPIES
Nadler E 1 , Eckert B 2 , Neumann P 2 1 Dana-Farber Cancer Institute, Boston, MA, USA; 2 Harvard University, Boston, MA, USA OBJECTIVES: The FDA's approval of Avastin, Erbitux and other novel agents has generated debate about the high cost and relative value of new cancer treatments. We sought to understand whether oncologists consider the therapies they employ to be cost-effective and to ascertain oncologists' cost-effectiveness thresholds for such therapies. METHODS: We surveyed 139 oncologists at two large academic hospitals in Boston. We asked respondents to provide estimates for the cost and effectiveness of Avastin (without appealing to published data) and whether they thought the treatment offered "good value." We also asked respondents to judge how large a gain in life-expectancy would justify a hypothetical new cancer therapeutic that cost $70,000 per year more than standard care. We used this information to calculate implied cost-effectiveness thresholds (in QALYs) for each respondent. Finally, we asked respondents about the role of cost in their treatment recommendations. RESULTS: Ninety oncologists (65%) completed the survey. Cost-effectiveness thresholds, derived from the hypothetical scenario, averaged over $300,000/QALY. Oncologists' estimates of the cost and survival benefit of Avastin implied a cost-effectiveness ratio in the same range, yet only 25% of oncologists believed Avastin offered good value. Oncologists who indicated a greater sensitivity to costs in their prescribing behavior had significantly lower costeffectiveness thresholds. CONCLUSIONS: Oncologists in an academic medical setting had implied cost-effectiveness thresholds that were roughly 6 times higher than a commonly cited standard in the U.S. of $50,000/QALY. When asked about specific scenarios, however, oncologists implied that very small gains in life expectancy were not worth the additional costs. Further, most oncologists were dubious about whether a recently approved therapy offered "good value." As expensive new cancer therapies enter clinical practice, oncologists' views about their role as practitioners may increasingly conflict with their beliefs about the value offered by these therapies.
CN4 EXPLICIT VALUATION OF PASS-THROUGH TECHNOLOGIES UNDER MEDICARE: IS IT FEASIBLE OR DESIRABLE?
Mohr P, Paserchia L, Kornfield T Centers for Medicare and Medicaid Services, Baltimore, MD, USA OBJECTIVES: To encourage early adoption, Medicare pays a temporary premium for selected new technologies (which are called pass-through technologies) in the outpatient setting. Implicit decisions are being made that the additional money spent for these pass-through technologies is worthwhile to the Medicare program. The goal of this study was to examine how implicit decisions being made for pass-through technologies compare with explicit cost-effectiveness criteria. METHODS:
We selected as case studies four technologies-two pass-through devices (embolic capture devices and silicone oil for retinal tamponade) and two pass-through drugs/biologicals (pegfilgrastim, triptorelin pamoate)-that Medicare estimates will account for the bulk of pass-through spending for 2004. We examined whether cost-effectiveness literature existed at the time of passthrough approval and critically examined its quality. We then used publicly-available data (e.g., Medicare claims and payment rates) to supplement available studies and examine costeffectiveness thresholds from Medicare's perspective. RESULTS: Cost-effectiveness studies were available for two of the four case study technologies at the time of their application review. The quality was variable. These studies, later publications, and our own analyses suggest some case study technologies could be costeffective in at least a subset of the Medicare population in which they are used. CONCLUSIONS: Cost-effectiveness information is sometimes available early in the life cycle of a technology and may provide additional useful information about whether and for which subpopulation Medicare should pay a premium for a new technology. Policy analysts must evaluate cost-effectiveness information critically, however, and may need to conduct supplemental analyses as a result. Medicare payment decisions do not now reflect any judgment about the value of that technology in terms of clinical benefit for incremental cost. The challenge to Medicare is to be able to limit pass-through payments to only those populations for whom there is proven value.
Methods & Concepts
MC1 WHY DO DIFFERENT MODELS COME TO DIFFERENT CONCLUSIONS?: A STUDY OF 8 COST-EFFECTIVENESS ANALYSES COMPARING COX-2 SPECIFIC INHIBITORS (COXIBS) AND NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
Risebrough NA 1 , Drummond M 2 , Neumann P 3 , Lising A 4 , Mittmann N 1 , Niculescu L 5 1 Hope Research Centre, Toronto, ON, Canada; 2 University of York, York, United Kingdom; 3 Harvard University, Boston, MA, USA; 4 Dymaxium Inc, Toronto, ON, Canada; 5 Pfizer Inc, New York, NY, USA OBJECTIVES: To critically evaluate published cost-effectiveness (CE) models and identify model elements contributing to the large variability in results. METHODS: A literature search of MEDLINE and EMBASE from 1985-2004 identified eight English-language CE models comparing coxibs to a nonsteroidal anti-inflammatory drug (NSAID)-alone regimen. Two studies were excluded due to unavailable model input data. Model time horizons ranged from six months to lifetime, and primary outcomes ranged from gastrointestinal (GI) events averted to lifeyears gained and quality-adjusted life-years gained. Common elements across models were minor GI discomfort/dyspepsia, moderate GI events/symptomatic ulcer, and severe GI events. Only two of the analyses included cardiovascular side effects. To compare model inputs we standardized all analyses to a sixmonth tree structure with the three GI side effects. Study probabilities were converted to six-month rates where necessary and costs were converted to $US using the purchasing power parity index. Cost offsets between coxibs and NSAIDs were calculated by multiplying the probability of the GI event by cost per event. RESULTS: The relative price used for coxibs compared with NSAIDs differed widely across studies (median over six months, $156; range, $14-$387). Differences in total GI event cost offsets were small (median, -$41; range -$53 to -$18). Moderate GI events provided the greatest GI event cost
